Variable expression of coxsackie-adenovirus receptor in thyroid tumors: Implications for adenoviral gene therapy

Derek K. Marsee, Douangsone D. Vadysirisack, Carl D. Morrison, Manju L. Prasad, Charis Eng, Quan Yang Duh, Katherine A Rauen, Richard T. Kloos, Sissy M. Jhiang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Adenoviral gene therapy represents a novel approach for the treatment of aggressive thyroid carcinomas. Both coxsackie-adenovirus receptor (CAR) and integrins have been shown to be the major determinants for adenoviral infectivity in many types of cancer cells, yet conflicting results have been reported. In this report we examine these factors mediating adenoviral infection in thyroid cells and to evaluate CAR expression in various types of thyroid cancer. We found that neither expression levels of CAR nor integrins are solely predictive of adenoviral infectivity in thyroid cells. However, the absence of CAR was associated with poor adenoviral infectivity in immortalized rat FRTL-5 cells. Moreover, preincubation with α-CAR antibody decreased infectivity in FTC 238 cells, a human thyroid tumor line. These results indicate that CAR does play a role in adenoviral infection of thyroid cells. Immunohistochemical analysis revealed that CAR is expressed at the cell surface in the majority of malignant thyroid tumors. We further show that adenoviral infectivity in some thyroid cancer cells can be improved by poly-L-lysine. Our study warrants a functional method to evaluate adenoviral infectivity should be developed and instituted prior to clinical trials of adenoviral gene therapy in patients with advanced thyroid cancer.

Original languageEnglish (US)
Pages (from-to)977-987
Number of pages11
JournalThyroid
Volume15
Issue number9
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Coxsackie and Adenovirus Receptor-Like Membrane Protein
Genetic Therapy
Thyroid Gland
Thyroid Neoplasms
Neoplasms
Integrins
Infection
Lysine
Clinical Trials

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Marsee, D. K., Vadysirisack, D. D., Morrison, C. D., Prasad, M. L., Eng, C., Duh, Q. Y., ... Jhiang, S. M. (2005). Variable expression of coxsackie-adenovirus receptor in thyroid tumors: Implications for adenoviral gene therapy. Thyroid, 15(9), 977-987. https://doi.org/10.1089/thy.2005.15.977

Variable expression of coxsackie-adenovirus receptor in thyroid tumors : Implications for adenoviral gene therapy. / Marsee, Derek K.; Vadysirisack, Douangsone D.; Morrison, Carl D.; Prasad, Manju L.; Eng, Charis; Duh, Quan Yang; Rauen, Katherine A; Kloos, Richard T.; Jhiang, Sissy M.

In: Thyroid, Vol. 15, No. 9, 09.2005, p. 977-987.

Research output: Contribution to journalArticle

Marsee, DK, Vadysirisack, DD, Morrison, CD, Prasad, ML, Eng, C, Duh, QY, Rauen, KA, Kloos, RT & Jhiang, SM 2005, 'Variable expression of coxsackie-adenovirus receptor in thyroid tumors: Implications for adenoviral gene therapy', Thyroid, vol. 15, no. 9, pp. 977-987. https://doi.org/10.1089/thy.2005.15.977
Marsee, Derek K. ; Vadysirisack, Douangsone D. ; Morrison, Carl D. ; Prasad, Manju L. ; Eng, Charis ; Duh, Quan Yang ; Rauen, Katherine A ; Kloos, Richard T. ; Jhiang, Sissy M. / Variable expression of coxsackie-adenovirus receptor in thyroid tumors : Implications for adenoviral gene therapy. In: Thyroid. 2005 ; Vol. 15, No. 9. pp. 977-987.
@article{b129be1f8c9c4130ba40919ac910dcb5,
title = "Variable expression of coxsackie-adenovirus receptor in thyroid tumors: Implications for adenoviral gene therapy",
abstract = "Adenoviral gene therapy represents a novel approach for the treatment of aggressive thyroid carcinomas. Both coxsackie-adenovirus receptor (CAR) and integrins have been shown to be the major determinants for adenoviral infectivity in many types of cancer cells, yet conflicting results have been reported. In this report we examine these factors mediating adenoviral infection in thyroid cells and to evaluate CAR expression in various types of thyroid cancer. We found that neither expression levels of CAR nor integrins are solely predictive of adenoviral infectivity in thyroid cells. However, the absence of CAR was associated with poor adenoviral infectivity in immortalized rat FRTL-5 cells. Moreover, preincubation with α-CAR antibody decreased infectivity in FTC 238 cells, a human thyroid tumor line. These results indicate that CAR does play a role in adenoviral infection of thyroid cells. Immunohistochemical analysis revealed that CAR is expressed at the cell surface in the majority of malignant thyroid tumors. We further show that adenoviral infectivity in some thyroid cancer cells can be improved by poly-L-lysine. Our study warrants a functional method to evaluate adenoviral infectivity should be developed and instituted prior to clinical trials of adenoviral gene therapy in patients with advanced thyroid cancer.",
author = "Marsee, {Derek K.} and Vadysirisack, {Douangsone D.} and Morrison, {Carl D.} and Prasad, {Manju L.} and Charis Eng and Duh, {Quan Yang} and Rauen, {Katherine A} and Kloos, {Richard T.} and Jhiang, {Sissy M.}",
year = "2005",
month = "9",
doi = "10.1089/thy.2005.15.977",
language = "English (US)",
volume = "15",
pages = "977--987",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Variable expression of coxsackie-adenovirus receptor in thyroid tumors

T2 - Implications for adenoviral gene therapy

AU - Marsee, Derek K.

AU - Vadysirisack, Douangsone D.

AU - Morrison, Carl D.

AU - Prasad, Manju L.

AU - Eng, Charis

AU - Duh, Quan Yang

AU - Rauen, Katherine A

AU - Kloos, Richard T.

AU - Jhiang, Sissy M.

PY - 2005/9

Y1 - 2005/9

N2 - Adenoviral gene therapy represents a novel approach for the treatment of aggressive thyroid carcinomas. Both coxsackie-adenovirus receptor (CAR) and integrins have been shown to be the major determinants for adenoviral infectivity in many types of cancer cells, yet conflicting results have been reported. In this report we examine these factors mediating adenoviral infection in thyroid cells and to evaluate CAR expression in various types of thyroid cancer. We found that neither expression levels of CAR nor integrins are solely predictive of adenoviral infectivity in thyroid cells. However, the absence of CAR was associated with poor adenoviral infectivity in immortalized rat FRTL-5 cells. Moreover, preincubation with α-CAR antibody decreased infectivity in FTC 238 cells, a human thyroid tumor line. These results indicate that CAR does play a role in adenoviral infection of thyroid cells. Immunohistochemical analysis revealed that CAR is expressed at the cell surface in the majority of malignant thyroid tumors. We further show that adenoviral infectivity in some thyroid cancer cells can be improved by poly-L-lysine. Our study warrants a functional method to evaluate adenoviral infectivity should be developed and instituted prior to clinical trials of adenoviral gene therapy in patients with advanced thyroid cancer.

AB - Adenoviral gene therapy represents a novel approach for the treatment of aggressive thyroid carcinomas. Both coxsackie-adenovirus receptor (CAR) and integrins have been shown to be the major determinants for adenoviral infectivity in many types of cancer cells, yet conflicting results have been reported. In this report we examine these factors mediating adenoviral infection in thyroid cells and to evaluate CAR expression in various types of thyroid cancer. We found that neither expression levels of CAR nor integrins are solely predictive of adenoviral infectivity in thyroid cells. However, the absence of CAR was associated with poor adenoviral infectivity in immortalized rat FRTL-5 cells. Moreover, preincubation with α-CAR antibody decreased infectivity in FTC 238 cells, a human thyroid tumor line. These results indicate that CAR does play a role in adenoviral infection of thyroid cells. Immunohistochemical analysis revealed that CAR is expressed at the cell surface in the majority of malignant thyroid tumors. We further show that adenoviral infectivity in some thyroid cancer cells can be improved by poly-L-lysine. Our study warrants a functional method to evaluate adenoviral infectivity should be developed and instituted prior to clinical trials of adenoviral gene therapy in patients with advanced thyroid cancer.

UR - http://www.scopus.com/inward/record.url?scp=26944480370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944480370&partnerID=8YFLogxK

U2 - 10.1089/thy.2005.15.977

DO - 10.1089/thy.2005.15.977

M3 - Article

C2 - 16187905

AN - SCOPUS:26944480370

VL - 15

SP - 977

EP - 987

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 9

ER -